Phase 2 Trial Defines Sunitinib Potential in Advanced Thyroid Cancer
While sunitinib failed as adjuvant treatment in advanced kidney cancer, this phase 2 study presented at the ongoing annual meeting of The Endocrine Society found that in patients with advanced thyroid cancer, sunitinib treatment resulted in median progression free survival of about 8 months. The authors think their results create sufficient evidence to initiate a phase 3 trial of the drug in thyroid cancer patients.
Oncology Clinic or Hospital, How Do Patients Decide?
New oncology payment models, 340B pricing and disproportionate share hospitals, and the significant difference in reimbursement rates for cancer care services are just some of the challenges faced by community oncology clinics. How do patients make informed decisions on where to go for care?
Healthcare Faces a Digital Dilemma
In an era when most industries easily share big, complicated digital files, healthcare still leans hard on paper printouts and fax machines.
HHS Expanding Access Research
HHS has released a plan to expand how its agencies make research results freely available to scientists and the public.
Managed Care Minute: March 7, 2015
A one-minute look at managed care news during the week of March 2, 2015, including oral arguments for King v. Burwell
and the approval of the first biosimilar in the United States.
California ED Forced to Close After EHR Failure
Antelope Valley Hospital in Lancaster, California, shut down its emergency department after the electronic health record and data system failed and the hospital had no backup plan in place.
CMS Has More Work to Do to Improve HealthCare.gov
The second open enrollment period for the Affordable Care Act went much smoother for consumers signing up for health plans through HealthCare.gov; however, CMS still has much work to do, according to a new report from the Government Accountability Office.
NIAID Trial to Evaluate Community-Based Hepatitis C Treatment
Gilead will be providing Harvoni free of cost to conduct a 600-person trial co-sponsored by the National Institute of Allergy and Infectious Diseases to evaluate if primary care physicians and other healthcare providers, such as nurse practitioners and physician assistants, can use a new antiviral therapy as effectively as specialist physicians.
FDA Approves First Biosimilar in US
Today the FDA approved the first biosimilar product in the United States. Zarxio (filgrastim-sndz), from Sandoz, Inc, is biosimilar to Amgen Inc’s Neupogen (filgrastim), which was first licensed in 1991.
Antidepressants Could Improve Cardiovascular Outcomes, Study Suggests
In patients with depression, antidepressants may be more important than statins, according to a study conducted at the Intermountain Medical Center Heart Institute in Salt Lake City, which will be presented at the American College of Cardiology's 64th Annual Scientific Session in San Diego.
Twitter a Predictor of Insurance Exchange Enrollment
Twitter can be used as a real-time measurement of public sentiment for the Affordable Care Act (ACA) and the positivity and negativity of tweets could be used to determine state-level marketplace enrollment, according to researchers.
New Guidelines for Treating Pediatric Hodgkin Lymphoma Issued
A guideline has been issued that outlines the use of 3-D computed tomography-based radiation therapy planning and volumetric image guidance to more effectively treat pediatric Hodgkin lymphoma and to reduce the radiation dose to normal tissue, thus decreasing the risk of late side effects.
NCI to Begin Search for a New Director
Harold Varmus, MD, who has led the National Cancer Institute at the National Institutes of Health for nearly 5 years, announced today that he will step down from his post, effective March 31, 2015.